BioLife Solutions Inc (NASDAQ:BLFS) Major Shareholder Casdin Partners Master Fund, L Acquires 20,000 Shares

Share on StockTwits

BioLife Solutions Inc (NASDAQ:BLFS) major shareholder Casdin Partners Master Fund, L acquired 20,000 shares of BioLife Solutions stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $15.15 per share, for a total transaction of $303,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of NASDAQ:BLFS traded up $0.94 on Thursday, reaching $16.49. 12,047 shares of the company’s stock were exchanged, compared to its average volume of 176,107. The firm has a market capitalization of $311.90 million, a price-to-earnings ratio of 117.14 and a beta of 1.35. BioLife Solutions Inc has a fifty-two week low of $9.15 and a fifty-two week high of $22.44. The business’s 50-day moving average is $16.33 and its two-hundred day moving average is $17.69. The company has a quick ratio of 5.33, a current ratio of 6.49 and a debt-to-equity ratio of 0.01.

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new position in shares of BioLife Solutions in the second quarter worth about $30,000. Alpine Woods Capital Investors LLC acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at approximately $170,000. Morgan Stanley grew its position in shares of BioLife Solutions by 17.5% in the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after purchasing an additional 1,713 shares during the period. Menta Capital LLC acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at approximately $202,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at approximately $283,000. 46.22% of the stock is currently owned by institutional investors.

A number of research analysts have commented on the stock. Maxim Group set a $26.00 price objective on shares of BioLife Solutions and gave the company a “buy” rating in a research note on Tuesday, September 17th. Zacks Investment Research upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Thursday, November 14th. BidaskClub downgraded shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Oppenheimer assumed coverage on shares of BioLife Solutions in a research note on Wednesday. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, ValuEngine downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $19.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: What are the benefits of buying treasury bonds?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Arena Pharmaceuticals, Inc.  Given Average Rating of “Hold” by Brokerages
Arena Pharmaceuticals, Inc. Given Average Rating of “Hold” by Brokerages
MASTERNET Reaches Market Capitalization of $4,359.00
MASTERNET Reaches Market Capitalization of $4,359.00
Storj  Tops 1-Day Trading Volume of $2.48 Million
Storj Tops 1-Day Trading Volume of $2.48 Million
SUEZ/ADR  Receives Consensus Recommendation of “Hold” from Brokerages
SUEZ/ADR Receives Consensus Recommendation of “Hold” from Brokerages
Nanometrics Incorporated  Receives $40.50 Average PT from Analysts
Nanometrics Incorporated Receives $40.50 Average PT from Analysts
TTC Price Tops $0.0254 on Major Exchanges
TTC Price Tops $0.0254 on Major Exchanges


© 2006-2019 Ticker Report